Android app on Google Play

Brean Murray Carret & Co. Starts Celsion Corp (CLSN) at Buy; Expectiing Positive Phase 3 Data This Year

February 16, 2012 7:37 AM EST Send to a Friend
Get Alerts CLSN Hot Sheet
Price: $3.40 --0%

Rating Summary:
    3 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade CLSN Now!
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on Celsion Corp (NASDAQ: CLSN) with a Buy. PT $7.00.

Brean analyst says, "We believe ThermoDox will be broadly adopted once it is approved. Due to the potential ability of ThermoDox to reduce the recurrence rate in intermediate HCC patients, we are optimistic about its adoption as the future standard of care, especially given how seamlessly ThermoDox can be integrated with RFA. Its effectiveness should increase the number of RFA procedures and enable the RFA/ThermoDox combination to take market share from procedures like TACE with chemotherapy. We view the use of an approved active agent (doxorubicin) as a risk mitigating factor for Celsion."

For an analyst ratings summary and ratings history on Celsion Corp click here. For more ratings news on Celsion Corp click here.

Shares of Celsion Corp closed at $1.91 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment